Nivolumab is a PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma. Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1).
- Mechanism
- Curator reviewed · 3 references
The ligands PD-L1 and PD-L2 bind to the PD-1 receptor on T-cells, inhibiting the action of these cells. Tumor cells express PD-L1 and PD-L2. Nivolumab binds to PD-1, preventing PD-L1 and PD-L2 from inhibiting the action of T-cells, restoring a patient's tumor-specific T-cell response.
- Primary indication
- Nivolumab is indicated in the following cancerous conditions: Melanoma adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, alone or in combination with ipilimumab for the adjuvant treatment of adult and...Curator reviewed · 218 structured indications
- Formula / weight
- C6362H9862N1712O1995S42 · 143597.3811 Da
- First approval
- Canada, 2015 · United States, 2014 · European Union, 2020
- Also known as
- NIVO
- Code names
- ABP 206 · BCD-263 · BMS-936558 · BMS-936558-01 · BMS-986298 · CMAB819 · GTPL7335 · MDX-1106 · NSC-748726 · ONO-4538
- Brand names
Resolves to
What you can answer from here — as of September 05, 2026
Which drugs share a target with Nivolumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account